This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
NATALEE is a randomized, phase 3, parallel-group clinical trial evaluating ribociclib with endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer. The registry lists invasive disease-free survival (iDFS) as the primary endpoint.
| Feature | NATALEE |
|---|---|
| Trial acronym | NATALEE |
| NCT identifier | NCT03701334 |
| Phase | Phase 3 |
| Status | ACTIVE_NOT_RECRUITING |
| Condition | Early Breast Cancer |
| Allocation | RANDOMIZED |
| Design model | PARALLEL |
| Masking | NONE |
| Primary purpose | TREATMENT |
| Enrollment | 5101 |
| Number of arms | 2 |
| Lead sponsor | Novartis Pharmaceuticals |
| Sponsor type | INDUSTRY |
| Start date | 2018-12-07 |
| Primary completion date | 2030-05-29 |
2. Clinical Question
The central clinical question is whether adding ribociclib to endocrine therapy can be evaluated as an adjuvant treatment strategy in patients with HR+/HER2- early breast cancer using invasive disease-free survival as the primary time-to-event endpoint.
Population
Patients with HR+/HER2- early breast cancer.
Intervention
Ribociclib with endocrine therapy as adjuvant treatment.
Comparator
The registry identifies two randomized study arms, with endocrine therapy listed as an intervention alongside ribociclib as the drug intervention. The registry record summarized here does not provide additional regimen detail for the comparator arm.
Primary question
How does the randomized treatment comparison relate to invasive disease-free survival in the study population?
3. Trial Design
Ribociclib + endocrine therapy
- Ribociclib is identified as the drug intervention.
- Endocrine Therapy (ET) is identified as an additional intervention.
- The treatment is described in the registry title as adjuvant treatment.
Comparator arm
- The study contains a second randomized arm.
- The registry record summarized here does not provide further comparator-regimen details.
- The parallel-group structure supports comparison of the randomized groups over follow-up.
4. Trial Timeline and Registry Status
Trial start
The registry lists 2018-12-07 as the study start date.
Active, not recruiting
The ClinicalTrials.gov record lists the study status as ACTIVE_NOT_RECRUITING.
Primary completion date
The registry lists 2030-05-29 as the primary completion date.
The distinction between study status and primary completion is important for interpreting a registry record. A study can be active without recruiting while the registry continues to track follow-up or other protocol activities through the listed completion date.
5. Primary Endpoint
| Endpoint | Registry definition | Time frame |
|---|---|---|
| Invasive Disease-Free Survival (iDFS) | Invasive Disease-Free Survival (iDFS) is defined as the time from the date of randomization to the date of the first event of local invasive breast recurrence, regional invasive recurrence, distant recurrence, death (any cause), contralateral invasive BC, or second primary non-breast invasive cancer (excluding basal and squamous cell carcinomas of the skin). iDFS will be assessed locally using STEEP criteria (Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials). | Up to approximately 139 months |
Why the endpoint is a time-to-event outcome
iDFS is not simply a proportion of patients who remain disease-free at one fixed date. It is defined as the time from randomization until the first qualifying event. Patients can therefore contribute different amounts of follow-up, and patients who have not experienced an event by the end of their observable follow-up can be censored according to the prespecified analysis rules.
The event definition combines several clinically relevant outcomes into a single time-to-first-event endpoint. The registry specifies local assessment using STEEP criteria.
6. Planned Analysis
The registry identifies invasive disease-free survival as the primary endpoint and specifies a time frame of up to approximately 139 months. No formal statistical analyses are posted in the ClinicalTrials.gov record summarized here, so the appropriate interpretation is a description of the planned statistical framework rather than an outcome comparison.
How iDFS would typically be analysed
Because iDFS is defined as time from randomization to the first qualifying event, a standard primary analysis would use survival-analysis methods. Kaplan-Meier estimation can describe the distribution of time to first iDFS event, including the handling of right-censored observations.
Kaplan-Meier estimation
A Kaplan-Meier curve can estimate the probability of remaining free of a qualifying iDFS event over time while accounting for patients whose event status is not yet observed at the end of follow-up.
Between-arm comparison
For a randomized two-arm time-to-event comparison, a log-rank test is commonly used to compare survival distributions, with a Cox proportional-hazards model commonly used to estimate a hazard ratio and confidence interval.
Event definition
The analysis must treat the first qualifying event as the endpoint event, regardless of which component of the composite iDFS definition occurs first.
Censoring
Patients without a qualifying event by their last evaluable follow-up can contribute information until that time. The validity of a survival analysis depends on appropriate prespecified censoring rules and follow-up procedures.
7. Statistical Methodology
Kaplan-Meier estimation
For a time-to-event endpoint such as iDFS, Kaplan-Meier estimation provides a nonparametric estimate of the probability of remaining event-free over time. It is particularly useful when follow-up times differ among patients, because it does not require every patient to have the same duration of observation.
where di is the number of events at time ti and ni is the number at risk immediately before that time.
Hazard ratio
A Cox proportional-hazards model is a standard approach for estimating the relative hazard between randomized groups in a time-to-event analysis. A hazard ratio below 1 would indicate a lower estimated instantaneous event rate in the numerator treatment group relative to the reference group, under the model.
A hazard ratio is not an absolute risk difference, a risk ratio at a specific time point, or the percentage of patients who benefit.
Log-rank comparison
A log-rank test is commonly used to compare time-to-event distributions between randomized treatment groups. It uses the observed and expected numbers of events over follow-up rather than reducing the entire analysis to a single fixed time point.
Confidence intervals
A confidence interval around a hazard ratio quantifies statistical uncertainty around the estimated relative treatment effect under the specified model and sampling framework. It does not describe the range of treatment effects experienced by individual patients.
Composite endpoint structure
The registry's iDFS definition contains multiple possible first events: local invasive breast recurrence, regional invasive recurrence, distant recurrence, death from any cause, contralateral invasive breast cancer, or second primary non-breast invasive cancer, with basal and squamous cell carcinomas of the skin excluded from the latter category. Statistical interpretation therefore depends on understanding both the overall composite endpoint and the clinical components that can trigger it.
8. Statistical Methods Explained
Why is iDFS analysed as a time-to-event endpoint?
Because the endpoint is defined by the time from randomization to the first qualifying event, two patients can have different follow-up durations and still contribute information to the analysis. A time-to-event framework preserves that timing information instead of treating all observations as if they occurred at one common assessment date.
What does the iDFS event definition mean statistically?
It means that the endpoint is triggered by the first qualifying event among several specified clinical outcomes. If a patient experiences one of those events, the time to that first event becomes the relevant event time for iDFS. This creates a composite endpoint whose interpretation reflects all of its included components.
Why use Kaplan-Meier estimation?
Kaplan-Meier estimation is designed for situations in which some patients have not experienced the event by the time their observed follow-up ends. Those patients are censored rather than treated as though they had experienced the event, allowing the analysis to use the information available before their censoring time.
What would a hazard ratio mean for iDFS?
A hazard ratio would compare the estimated instantaneous rate of a qualifying iDFS event between the randomized groups. For example, a hazard ratio below 1 would represent a lower estimated event hazard in the treatment group relative to the reference group. It would not mean that the same percentage of every patient avoided an event.
Why does the confidence interval matter?
The point estimate alone gives only one estimate of the treatment contrast. Its confidence interval shows how precisely that effect has been estimated under the statistical model. A wide interval indicates greater uncertainty, while a narrower interval indicates greater precision.
What does the p-value mean in a time-to-event analysis?
When a formal hypothesis test is prespecified, the p-value measures how compatible the observed data are with the null hypothesis under the test's assumptions. It does not measure the size of the treatment effect, the clinical importance of the result, or the probability that the null hypothesis is true.
Why does the proportional-hazards assumption matter?
A Cox hazard ratio is often interpreted as a relative event-rate comparison over follow-up. If the relative hazards change substantially over time, a single hazard ratio may provide an incomplete description of the treatment effect. Kaplan-Meier estimates and clinically meaningful time-specific measures can therefore complement the hazard ratio.
9. Analysis Population and Randomization
The registry identifies the study as randomized with 5101 enrolled participants and two arms. Randomization is the central design feature that supports comparison of outcomes according to assigned treatment rather than according to treatment received after assignment.
| Design feature | Registry information | Statistical relevance |
|---|---|---|
| Allocation | RANDOMIZED | Randomization supports comparability of treatment groups in expectation. |
| Design model | PARALLEL | The two randomized groups are followed as separate parallel treatment arms. |
| Masking | NONE | The registry identifies the trial as unmasked. |
| Number of arms | 2 | The primary treatment comparison is between two randomized groups. |
| Enrollment | 5101 | Provides the overall size of the randomized study population reported in the registry. |
10. What the Primary Endpoint Can and Cannot Tell Us
iDFS can summarize the time from randomization until the first occurrence of one of the prespecified invasive recurrence, death, contralateral invasive breast cancer, or second-primary-cancer events included in the registry definition.
Because several event types are combined into one composite endpoint, an overall iDFS comparison does not by itself establish that every component of the endpoint changes to the same degree.
Two patients can experience the same type of qualifying event but at different times. A time-to-event analysis retains that distinction, whereas a simple event proportion would not.
A hazard ratio, if reported, would describe a relative treatment contrast. Time-specific iDFS probabilities and other absolute measures would provide a different perspective on the magnitude and timing of disease-free benefit.
11. Composite Endpoint Interpretation
The iDFS endpoint contains six broad event categories in the registry definition: local invasive breast recurrence, regional invasive recurrence, distant recurrence, death from any cause, contralateral invasive breast cancer, and second primary non-breast invasive cancer, with basal and squamous cell carcinomas of the skin excluded from the latter category.
| iDFS component | Role in the endpoint |
|---|---|
| Local invasive breast recurrence | Qualifying first event |
| Regional invasive recurrence | Qualifying first event |
| Distant recurrence | Qualifying first event |
| Death from any cause | Qualifying first event |
| Contralateral invasive breast cancer | Qualifying first event |
| Second primary non-breast invasive cancer | Qualifying first event, excluding basal and squamous cell carcinomas of the skin |
This structure illustrates an important statistical principle: a composite endpoint is interpreted at the level of the prespecified combined outcome. If component frequencies differ substantially, the overall treatment effect can be driven more strongly by some components than others.
12. Missing Data, Censoring, and Follow-Up
The registry defines iDFS from randomization through the first qualifying event and specifies a time frame of up to approximately 139 months. In a conventional survival analysis, patients who have not experienced a qualifying event by their last evaluable follow-up are censored according to prespecified rules.
Censoring is not an event
A censored observation contributes information up to the censoring time but does not count as an iDFS event at that time.
Follow-up affects precision
More observed events generally provide more information for estimating a time-to-event treatment contrast, while incomplete follow-up can increase uncertainty.
Censoring assumptions matter
Survival methods rely on assumptions about the relationship between censoring and future event risk. Informative loss to follow-up can threaten the validity of a conventional analysis.
Time frame is part of interpretation
The registry specifies an iDFS time frame of up to approximately 139 months, so the endpoint is inherently longitudinal rather than a single short-term assessment.
13. Limitations
- No posted statistical analyses: the ClinicalTrials.gov record does not contain posted statistical analyses for the primary endpoint in the record summarized here.
- No posted outcome estimates: the registry information summarized here does not provide numerical iDFS estimates, hazard ratios, confidence intervals, or p-values.
- Composite endpoint: iDFS combines several distinct clinical events. An overall treatment comparison does not by itself show whether every component contributes equally to the observed effect.
- Unmasked design: the registry lists masking as none. Lack of masking can be relevant to outcome assessment and treatment management, although the magnitude of any resulting bias depends on the endpoint and assessment procedures.
- Long follow-up: the registry specifies an iDFS time frame of up to approximately 139 months. Longitudinal interpretation requires attention to censoring, follow-up completeness, and changes occurring during the study period.
- Endpoint assessment: the registry states that iDFS will be assessed locally using STEEP criteria. Local assessment can have different sources of variability from centrally reviewed assessments.
- Registry scope: the ClinicalTrials.gov record provides the registered endpoint definition and trial-design information, but a full statistical analysis requires the prespecified statistical analysis plan and the corresponding reported results.
14. Why This Trial Matters Statistically
NATALEE is a useful statistical teaching case because its primary endpoint combines the central features of modern adjuvant oncology time-to-event analysis: randomization, a parallel two-arm design, a composite disease-free endpoint, potentially unequal follow-up, censoring, and a long observation window.
| Concept | How it appears in NATALEE |
|---|---|
| Randomization | The registry classifies allocation as RANDOMIZED. |
| Parallel-group design | The registry classifies the design model as PARALLEL with two arms. |
| Time-to-event analysis | iDFS is defined as time from randomization to the first qualifying event. |
| Composite endpoint | iDFS includes recurrence, death, contralateral invasive breast cancer, and second primary non-breast invasive cancer events under the registry definition. |
| Censoring | Time-to-event methodology can accommodate participants without a qualifying event at the end of observable follow-up. |
| Hazard ratio | A Cox model would commonly provide a relative time-to-event treatment estimate for an endpoint of this type. |
| Kaplan-Meier estimation | A standard way to describe event-free survival over time. |
| Long-term follow-up | The registry specifies an iDFS time frame of up to approximately 139 months. |
| Local endpoint assessment | The registry specifies local assessment using STEEP criteria. |
15. Statistical Interpretation Framework
The treatment question begins with the randomized comparison and the prespecified iDFS endpoint. The relevant outcome is time from randomization to the first qualifying event defined by the registry.
Rather than reducing follow-up to whether an event occurred at one fixed date, survival analysis uses both event occurrence and the amount of observed follow-up for each participant.
Kaplan-Meier methods can describe the probability of remaining free of a qualifying iDFS event over time, subject to the assumptions underlying censoring.
A log-rank test can compare the time-to-event distributions, while a Cox model can summarize the relative treatment effect through a hazard ratio and confidence interval.
The final statistical interpretation should consider that iDFS is triggered by multiple possible first events. A treatment effect on the composite does not automatically imply identical effects on each component.
16. Clinical Interpretation vs Statistical Interpretation
Statistical interpretation
The registry establishes a randomized, two-arm, parallel-group framework with iDFS as the primary time-to-event endpoint. Formal numerical statistical results are not posted in the ClinicalTrials.gov record summarized here.
Clinical interpretation
The clinical question concerns adjuvant treatment of HR+/HER2- early breast cancer using ribociclib with endocrine therapy. Interpretation of treatment benefit requires the eventual iDFS event data and corresponding prespecified statistical analyses.
17. Important Questions for Interpreting Future iDFS Results
| Question | Why it matters |
|---|---|
| What is the iDFS hazard ratio? | Provides a relative comparison of the estimated instantaneous event rates between randomized groups. |
| What is the 95% confidence interval? | Shows the statistical uncertainty surrounding the estimated treatment effect. |
| What is the p-value and what hypothesis was tested? | Places the statistical evidence in the context of the prespecified hypothesis-testing framework. |
| What are the Kaplan-Meier iDFS estimates at clinically relevant times? | Provides an absolute time-specific description that complements the hazard ratio. |
| Which iDFS components account for the observed events? | Clarifies what is driving the composite endpoint. |
| How were censoring and competing clinical events handled? | These decisions can affect interpretation of a composite time-to-event endpoint. |
| Was the proportional-hazards assumption appropriate? | If hazards change substantially over time, a single Cox hazard ratio may not fully describe the treatment contrast. |
18. Registry-Based Trial Summary
The ClinicalTrials.gov record identifies NATALEE as a phase 3, randomized, parallel-group trial with two arms and 5101 enrolled participants. The study evaluates ribociclib with endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer. The primary endpoint is invasive disease-free survival, defined from randomization to the first specified recurrence, death, contralateral invasive breast cancer, or second primary non-breast invasive cancer event, with basal and squamous cell carcinomas of the skin excluded from that second-primary category.
19. Sources
- ClinicalTrials.gov record: NCT03701334.
Continue through the Clinical Biostats knowledge graph
Explore the broader Clinical Biostats library for statistical methods, clinical-trial concepts, and analytical workflows.
20. Record Summary
NATALEE provides a clear example of how a randomized phase 3 adjuvant oncology trial can be framed statistically around a composite time-to-event endpoint. The registry identifies a randomized, parallel two-arm design, enrollment of 5101 participants, and invasive disease-free survival as the primary endpoint over a time frame of up to approximately 139 months. For statistical interpretation, the central concepts are the construction of the iDFS event, preservation of time-to-event information, appropriate handling of censoring, comparison of randomized groups, and careful interpretation of a composite endpoint.